User profiles for SF Scott
Susanna Foxworthy ScottAssistant Professor @ Butler University Verified email at butler.edu Cited by 173 |
In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
PL Shah, SF Scott, RA Knight, C Marriott, C Ranasinha… - Thorax, 1996 - thorax.bmj.com
BACKGROUND: Viscoelastic secretions in cystic fibrosis cause impaired mucus clearance
and persistence of bacteria within the lung. The abnormal rheology is partly due to the …
and persistence of bacteria within the lung. The abnormal rheology is partly due to the …
Research administration around the world
S Kerridge, SF Scott - Research Management Review, 2018 - kar.kent.ac.uk
… The data cleansing process (see Kerridge & Scott, 2017a) included a 20point data analysis
plan (see Kerridge & Scott, 2017b), starting with SPSS Statistics (IBM Corp., 2016) orientation…
plan (see Kerridge & Scott, 2017b), starting with SPSS Statistics (IBM Corp., 2016) orientation…
Persistent disparities in cervical cancer screening uptake: knowledge and sociodemographic determinants of Papanicolaou and human papillomavirus testing among …
Objectives Cervical cancer is the second-most common type of cancer among women aged
15-44, and racial, ethnic, and economic disparities exist in survival rates despite widely …
15-44, and racial, ethnic, and economic disparities exist in survival rates despite widely …
Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype
SR Thomas, SA Kharitonov, SF Scott, ME Hodson… - Chest, 2000 - Elsevier
Study objectives Inducible nitric oxide synthase (iNOS) is upregulated in a number of
inflammatory lung conditions, and exhaled nitric oxide (NO) concentration is increased. However, …
inflammatory lung conditions, and exhaled nitric oxide (NO) concentration is increased. However, …
Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment
…, CA Johnson, MC Light, SF Scott… - European …, 1995 - Eur Respiratory Soc
Chronic pulmonary infection is the major cause of morbidity and mortality in cystic fibrosis (CF).
Recombinant human deoxyribonuclease (rhDNase) in vitro has been shown to …
Recombinant human deoxyribonuclease (rhDNase) in vitro has been shown to …
[HTML][HTML] Beyond postural drainage and percussion: Airway clearance in people with cystic fibrosis
JA Pryor, E Tannenbaum, SF Scott, J Burgess… - Journal of Cystic …, 2010 - Elsevier
BACKGROUND: Evidence indicates that there are no statistically significant differences in
effectiveness among the airway clearance techniques (ACTs) of active cycle of breathing, …
effectiveness among the airway clearance techniques (ACTs) of active cycle of breathing, …
Qualitative assessment of bad news delivery practices during miscarriage diagnosis
… Therefore, Bute and Scott each coded two transcripts and Brann coded one transcript (N
= 5). The authors met regularly to discuss data and analysis. … Susanna Foxworthy Scott …
= 5). The authors met regularly to discuss data and analysis. … Susanna Foxworthy Scott …
A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period
PL Shah, S Conway, SF Scott, M Rainisio, M Wildman… - Respiration, 2001 - karger.com
Background: Chronic endobronchial sepsis and profuse airway secretions dominate
pulmonary disease in cystic fibrosis. Recombinant human DNase I (dornase alfa) reduces the …
pulmonary disease in cystic fibrosis. Recombinant human DNase I (dornase alfa) reduces the …
Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis
PL Shah, SF Scott, DM Geddes, ME Hodson - Respiratory medicine, 1995 - Elsevier
Recombinant human DNase I (rhDNase) has been shown to improve pulmonary function in
patients treated for up to 6 months. A cohort of 52 cystic fibrosis patients with a FVC >40% …
patients treated for up to 6 months. A cohort of 52 cystic fibrosis patients with a FVC >40% …
Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
PL Shah, SF Scott, HJ Fuchs, DM Geddes, ME Hodson - Thorax, 1995 - thorax.bmj.com
BACKGROUND--A phase II multicentre double blind placebo controlled study in 1993 showed
that short term treatment (10 days) with recombinant human DNase I (rhDNase) was safe …
that short term treatment (10 days) with recombinant human DNase I (rhDNase) was safe …